Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 May;146(5):662-7.
doi: 10.1016/j.jpeds.2004.12.022.

Infliximab treatment for refractory Kawasaki syndrome

Jane C Burns  1 , Wilbert H Mason, Sarmistha B Hauger, Hillel Janai, John F Bastian, Julie D Wohrley, Ian Balfour, Cynthia A Shen, Edward D Michel, Stanford T Shulman, Marian E Melish
Affiliations

Infliximab treatment for refractory Kawasaki syndrome

Jane C Burns et al. J Pediatr. 2005 May.

Abstract

Objective: To evaluate the use of tumor necrosis factor (TNF)-alpha blockade for treatment of patients with Kawasaki syndrome (KS) who fail to become afebrile or who experience persistent arthritis after treatment with intravenous gamma globulin (IVIG) and high-dose aspirin.

Study design: Cases were retrospectively collected from clinicians throughout the United States who had used infliximab, a chimeric murine/human immunoglobulin (Ig)G1 monoclonal antibody that binds specifically to human TNF-alpha-1, for patients with KS who had either persistent arthritis or persistent or recrudescent fever > or =48 hours following infusion of 2 g/kg of IVIG.

Results: Response to therapy with cessation of fever occurred in 13 of 16 patients. C-reactive protein (CRP) level was elevated in all but one patient before infliximab infusion, and the level was lower following infusion in all 10 patients in whom it was re-measured within 48 hours of treatment. There were no infusion reactions to infliximab and no complications attributed to infliximab administration in any of the patients.

Conclusion: The success of TNF-alpha blockade in this small series of patients suggests a central role of TNF-alpha in KS pathogenesis. Controlled, randomized clinical trials are warranted to determine the role of anti-TNF-alpha therapy in KS.

PubMed Disclaimer

Comment in

  • Infliximab for Kawasaki syndrome.
    Saji T, Kemmotsu Y. Saji T, et al. J Pediatr. 2006 Sep;149(3):426; author reply 426. doi: 10.1016/j.jpeds.2005.07.039. J Pediatr. 2006. PMID: 16939768 No abstract available.

MeSH terms